盐酸昂丹司琼口腔崩解片预防胃癌辅助同步放化疗所致恶心呕吐疗效观察

Ondansetron hydrochloride orally disintegrating tablets in preventing nausea and vomiting caused by chemoradiotherapy in patients with gastric cancer

目的：评价盐酸昂丹司琼口腔崩解片预防胃癌辅助同步放化疗致恶心呕吐的疗效和安全性.方法：将接受辅助同步放化疗的52例胃癌患者分为实验组（盐酸昂丹司琼口腔崩解片组,26例）和对照组（甲氧氯普胺组,26例）,观察2组恶心呕吐的发生率、不良反应和生活质量.结果：实验组的总体恶心呕吐的发生率明显低于对照组（46.2％ vs 88.5％,P＜0.05）,其中实验组和对照组3～4级以上恶心呕吐的发生率分别为15.4％和34.6％（P＜0.05）.结论：盐酸昂丹司琼口腔崩解片预防胃癌放化疗所致恶心呕吐疗效确切,安全性良好.

Objective：To evaluate the efficacy and safety of ondansetron hydrochloride orally disintegrating tablets in preventing nausea and vomiting in patients undergoing adjuvant chemoradiotherapy.Methods：Postoperative gastric cancer patients who received adjuvant chemoradiotherapy were divided into study group （ondansetron hydrochloride orally disintegrating tablets group,26 cases） and control group （metoclopramide group,26 cases）.The incidence of nausea and vomiting,adverse events and life quality were observed in the two groups.Results：The total rate of nausea and vomiting in study group was lower than that in the control group （46.2％ vs 88.5 ％,P ＜ 0.05）,and the rate of Grade 3 ～ 4 nausea and vomiting in study group and control group was 15.4％ and 34.6％ respectively （P ＜ 0.05）.Conclusion：Ondansetron hydrochloride orally disintegrating tablet shows good effect and is well tolerated in control of nausea and vomiting in patients with gastric cancer treated with chemoradiotherapy.